ArticleClinical and experimental medicine2025
LncRNA SNHG11 expression in acute myeloid leukemia patients and its relationship with the biology of acute myeloid leukemia cells.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAcute myeloid leukemia (AML) is a malignancy involving the blood and bone marrow, marked by the uncontrolled growth and development of myeloid cells. LncRNA small nucleolar RNA host gene 11 (SNHG11) is aberrantly expressed in various cancers. Objective of current research was to explore the SNHG1 expression in AML patients and further explore its role and mechanisms in AML cell biology.
methodsSNHG11 and miR-122-5p levels were detected by quantitative PCR. The diagnostic potential of SNHG11 was assessed via ROC curve analysis. Effects of SNHG11 on the 5-year overall survival (OS) of AML was detected by Kaplan-Meier (KM) curve. sh-SNHG11 was transfected into MOLM-13 cells to explore the growth and apoptosis of MOLM-13 cells. Cell growth and apoptosis were assessed using the CCK-8 kit and a flow cytometer.
resultsSNHG11 level was significantly elevated in AML patients. SNHG11 had diagnostic value for AML (AUC = 0.827, sensitivity = 72.58%, specificity = 79.74%). High-SNHG11 group had shorter OS than low group (P < 0.001, log-rank test). SNHG11 (HR = 2.036, 95% CI = 1.103-3.758) was a risk factor for poor AML prognosis. sh-SNHG11 markedly suppressed proliferation and increased apoptosis in MOLM-13 cells via miR-122-5p.
conclusionSNHG11 could diagnose AML from healthy controls and related to poor prognosis of AML patients. SNHG11 could impact cell biology through miR-122-5p.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.